621 related articles for article (PubMed ID: 33172899)
1. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
[TBL] [Abstract][Full Text] [Related]
2. EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma.
Gao M; Fu Y; Zhou W; Gui G; Lal B; Li Y; Xia S; Ji H; Eberhart CG; Laterra J; Ying M
Cancer Res; 2021 Jul; 81(13):3580-3592. PubMed ID: 33910930
[TBL] [Abstract][Full Text] [Related]
3. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
[TBL] [Abstract][Full Text] [Related]
4. Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.
Barrette AM; Ronk H; Joshi T; Mussa Z; Mehrotra M; Bouras A; Nudelman G; Jesu Raj JG; Bozec D; Lam W; Houldsworth J; Yong R; Zaslavsky E; Hadjipanayis CG; Birtwistle MR; Tsankova NM
Neuro Oncol; 2022 May; 24(5):694-707. PubMed ID: 34657158
[TBL] [Abstract][Full Text] [Related]
5. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
[TBL] [Abstract][Full Text] [Related]
7. Induction of store-operated calcium entry (SOCE) suppresses glioblastoma growth by inhibiting the Hippo pathway transcriptional coactivators YAP/TAZ.
Liu Z; Wei Y; Zhang L; Yee PP; Johnson M; Zhang X; Gulley M; Atkinson JM; Trebak M; Wang HG; Li W
Oncogene; 2019 Jan; 38(1):120-139. PubMed ID: 30082911
[TBL] [Abstract][Full Text] [Related]
8. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ.
Edwards DN; Ngwa VM; Wang S; Shiuan E; Brantley-Sieders DM; Kim LC; Reynolds AB; Chen J
Sci Signal; 2017 Dec; 10(508):. PubMed ID: 29208682
[TBL] [Abstract][Full Text] [Related]
9. Nogo-B fosters HCC progression by enhancing Yap/Taz-mediated tumor-associated macrophages M2 polarization.
Zhao X; Wang X; You Y; Wen D; Feng Z; Zhou Y; Que K; Gong J; Liu Z
Exp Cell Res; 2020 Jun; 391(1):111979. PubMed ID: 32246992
[TBL] [Abstract][Full Text] [Related]
10. HDAC9 promotes glioblastoma growth via TAZ-mediated EGFR pathway activation.
Yang R; Wu Y; Wang M; Sun Z; Zou J; Zhang Y; Cui H
Oncotarget; 2015 Apr; 6(10):7644-56. PubMed ID: 25760078
[TBL] [Abstract][Full Text] [Related]
11. The impact of interaction between verteporfin and yes-associated protein 1/transcriptional coactivator with PDZ-binding motif-TEA domain pathway on the progression of isocitrate dehydrogenase wild-type glioblastoma.
Osama M; Essibayi MA; Osama M; Ibrahim IA; Nasr Mostafa M; Şakir Ekşi M
J Cent Nerv Syst Dis; 2023; 15():11795735231195760. PubMed ID: 37600236
[TBL] [Abstract][Full Text] [Related]
12. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
[TBL] [Abstract][Full Text] [Related]
13. Feedforward loop between IMP1 and YAP/TAZ promotes tumorigenesis and malignant progression in glioblastoma.
Yang J; Wu X; Wang J; Guo X; Chen J; Yang X; Zhong J; Li X; Deng Z
Cancer Sci; 2023 May; 114(5):2053-2062. PubMed ID: 36308276
[TBL] [Abstract][Full Text] [Related]
14. Targeted inhibition of YAP/TAZ alters the biological behaviours of keloid fibroblasts.
Gao N; Lu L; Ma X; Liu Z; Yang S; Han G
Exp Dermatol; 2022 Mar; 31(3):320-329. PubMed ID: 34623712
[TBL] [Abstract][Full Text] [Related]
15. Actin like-6A promotes glioma progression through stabilization of transcriptional regulators YAP/TAZ.
Ji J; Xu R; Zhang X; Han M; Xu Y; Wei Y; Ding K; Wang S; Bin Huang ; Chen A; Di Zhang ; Jiang Z; Xu S; Zhang Q; Li W; Ni S; Wang J; Li X
Cell Death Dis; 2018 May; 9(5):517. PubMed ID: 29725063
[TBL] [Abstract][Full Text] [Related]
16. c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein.
Bunda S; Heir P; Li ASC; Mamatjan Y; Zadeh G; Aldape K
Mol Cancer Res; 2020 May; 18(5):774-786. PubMed ID: 32029440
[TBL] [Abstract][Full Text] [Related]
17. Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma.
Saunders JT; Holmes B; Benavides-Serrato A; Kumar S; Nishimura RN; Gera J
J Neurooncol; 2021 Apr; 152(2):217-231. PubMed ID: 33511508
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous knockdown of YAP and TAZ increases apoptosis of hepatocellular carcinoma cells under hypoxic condition.
Yan B; Li T; Shen L; Zhou Z; Liu X; Wang X; Sun X
Biochem Biophys Res Commun; 2019 Jul; 515(2):275-281. PubMed ID: 31146919
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of YAP/TAZ pathway contributes to the cytotoxicity of silibinin in MCF-7 and MDA-MB-231 human breast cancer cells.
Fu J; Liu W; Liu S; Zhao R; Hayashi T; Zhao H; Xiang Y; Mizuno K; Hattori S; Fujisaki H; Ikejima T
Cell Signal; 2024 Jul; 119():111186. PubMed ID: 38643945
[TBL] [Abstract][Full Text] [Related]
20. Drak/STK17A Drives Neoplastic Glial Proliferation through Modulation of MRLC Signaling.
Chen AS; Wardwell-Ozgo J; Shah NN; Wright D; Appin CL; Vigneswaran K; Brat DJ; Kornblum HI; Read RD
Cancer Res; 2019 Mar; 79(6):1085-1097. PubMed ID: 30530503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]